Cabaletta Bio (CABA) EBITDA (2018 - 2025)

Cabaletta Bio's EBITDA history runs 8 years deep, the most recent figure standing at -$42.6 million for Q4 2025.

• On a quarterly basis, EBITDA fell 26.12% year-over-year to -$42.6 million in Q4 2025; TTM through Dec 2025 was -$172.2 million, a 37.64% decrease from a year earlier, with the FY2025 full-year figure at -$172.2 million, down 37.64% from the prior year.
• EBITDA grew to -$42.6 million in Q4 2025 per CABA's latest filing, from -$46.6 million in the prior quarter.
• Across five years, EBITDA topped out at -$9.7 million in Q1 2021 and bottomed at -$46.6 million in Q3 2025.
• The 5-year median for EBITDA is -$17.8 million (2023), against an average of -$23.6 million.
• Across the five-year window, EBITDA slipped 1.86% in 2022 and plunged 90.55% in 2024, its largest moves.
• Year by year, EBITDA stood at -$13.9 million in 2021, then fell by 17.34% to -$16.3 million in 2022, then plunged by 41.98% to -$23.1 million in 2023, then slumped by 45.96% to -$33.8 million in 2024, then declined by 26.12% to -$42.6 million in 2025.
• Per Business Quant, the three latest CABA EBITDA figures stand at -$42.6 million (Q4 2025), -$46.6 million (Q3 2025), and -$45.9 million (Q2 2025).